Explorer les evidences

5,3 %Among 76 patients followed-up at endpoint, 5.3% (4/76) harbored HIV drug resistance.

CamerounVIH/sidaobservé 2009-2011publié 2013PLoS ONEOpenAlexdocument de 8 observationsDOI 10.1371/journal.pone.0072680

23 %Among 110 HIV-1-infected, drug-naïve Cameroonians, 25 (23%) had unclassifiable protease (PR) sequences.

CamerounVIH/sidapublié 2002Journal of Clinical MicrobiologyOpenAlexdocument de 12 observations

0,92 probabilityThe survival probability was 0.92 at 12 months.

CamerounVIH/sidaobservé 12 monthspublié 2005Antiviral TherapyOpenAlexdocument de 8 observationsDOI 10.1177/135965350501000208

Systolic blood pressure was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublié 2013Diabetes & metabolismeurope_pmcdocument de 12 observations

11 %The prevalence of the 376S substitution in reverse transcriptase sequences was 11% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

77,9 %Including HIV indeterminate samples in test efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%.

CamerounVIH/sidapublié 2009PLoS ONEOpenAlexdocument de 3 observationsDOI 10.1371/journal.pone.0007702

19,6 %Ten out of 51 patients (19.6%) with NNRTI resistance accumulated mutations that may have compromised etravirine use.

CamerounVIH/sidapublié 2013Journal of the International AIDS Societyeurope_pmcdocument de 4 observations

67,7 %Viral suppression in the ART 48-60 group was 67.7%.

CamerounVIH/sidapublié 2018EClinicalMedicineOpenAlexdocument de 3 observationsDOI 10.1016/j.eclinm.2018.06.005